unfold
protein
respons
upr
mechan
elicit
whenev
protein
fold
compromis
insid
endoplasm
reticulum
er
last
year
interest
upr
signal
network
increas
due
implic
er
stress
mechan
wide
rang
patholog
includ
infect
ischem
injuri
neurodegen
disord
metabol
diseas
neoplasia
stress
condit
upr
activ
essenti
restor
proteinfold
homeostasi
howev
damag
cell
highli
sever
chronic
er
stress
upr
signal
lead
cell
apoptosi
mammal
particular
unfold
protein
recogn
er
lumen
chaperon
molecul
immunoglobulin
heavi
chainbind
protein
dissoci
three
transmembran
protein
pkrlike
er
kinas
perk
activ
transcript
factor
inositolrequir
enzym
synerg
action
three
protein
also
known
upr
sensor
lead
translat
transcript
downstream
pathway
lead
less
protein
product
activ
gene
encod
import
protein
fold
process
chaperon
presenc
unfold
protein
insid
er
lumen
result
mani
differ
physiolog
condit
cell
develop
differenti
high
product
secret
protein
genet
mutat
oxid
stress
may
even
respons
certain
pathogen
includ
viral
infect
viral
activ
upr
may
specif
caus
product
new
viral
particl
due
high
load
viral
protein
product
er
infect
howev
certain
downstream
effector
necessarili
benefici
viral
replic
eg
protein
degrad
ubiquitin
proteasomedepend
process
known
erassoci
degrad
erad
apoptosi
induct
nonetheless
virus
also
capabl
avoid
activ
sever
mechan
upr
pathway
show
abil
modul
cellular
stress
respons
promot
cell
surviv
effici
viral
replic
creat
environ
favor
replic
effect
hiv
infect
upr
pathway
scarc
investig
regard
hiv
target
cell
particular
vitro
studi
use
jurkat
tcell
line
promonocyt
cell
show
hiv
respons
induc
transcript
translat
lead
accumul
factor
acut
phase
infect
report
also
indic
trigger
reactiv
hiv
replic
infect
cell
mechan
mediat
viral
protein
tat
suggest
er
stress
event
lead
high
express
may
relev
end
viral
latenc
addit
report
shown
proteas
inhibitor
use
part
arv
therapi
respons
pharmacolog
activ
upr
pathway
vitro
howev
despit
known
pharmacolog
effect
arv
drug
hiv
possibl
upr
mechan
modul
hiv
host
cell
complet
elucid
thu
interest
investig
upr
pathway
modul
hiv
infect
via
assess
express
uprrel
protein
vitro
vivo
condit
also
consid
influenc
arv
drug
stress
respons
first
report
show
uprrel
protein
express
hiv
target
cell
deriv
directli
hivinfect
patient
receiv
differ
arv
therapi
specif
report
hiv
infect
respons
activ
stressrespons
compon
arv
therapi
contribut
chang
upr
pathway
activ
profil
base
vitro
vivo
analys
determin
whether
hiv
infect
induc
chaperon
bip
pbmc
infect
hiv
submit
differ
arv
treatment
fig
hiv
replic
pbmc
normal
donor
differ
condit
shown
addit
file
tabl
furthermor
noninfect
cell
submit
arv
treatment
condit
identifi
pharmacolog
modul
upr
activ
drug
select
studi
lamivudin
nucleosid
revers
transcriptas
inhibitor
ritonavir
rtv
proteas
inhibitor
use
separ
togeth
western
blot
result
densitometri
analysi
show
arv
drug
use
induc
signific
effect
bip
express
either
noninfect
infect
cluster
howev
infect
cell
without
treatment
arv
treatment
show
significantli
higher
express
chaperon
comparison
noninfect
cell
demonstr
densitometri
analysi
profil
bip
express
found
vivo
assay
perform
use
cell
volunt
fig
monocyt
lymphocyteenrich
popul
control
group
repres
cell
healthi
blood
donor
show
lower
express
bip
contrast
increas
express
chaperon
observ
hivinfect
cell
alreadi
observ
vitro
assay
type
arv
therapi
appear
determin
induct
bip
express
monocyt
hiv
patient
bip
express
significantli
higher
p
lymphocyt
also
present
significantli
higher
express
bip
group
similar
express
cell
obtain
hivinfect
patient
treatment
without
proteas
inhibitor
p
data
suggest
hiv
infect
capabl
induc
bip
express
vitro
vivo
condit
potenti
result
environ
favor
continu
protein
fold
signific
indic
upr
activ
express
phosphoryl
form
analyz
vitro
vivo
condit
western
blot
phosphoryl
repres
activ
lead
translat
inhibit
insid
cell
condit
certain
specif
gene
relat
er
stress
respons
express
attenu
furthermor
phosphoryl
consequ
previou
perk
activ
suggest
activ
upr
sensor
present
studi
differ
level
observ
noninfect
pbmc
regardless
arv
treatment
howev
hivinfect
pbmc
submit
arv
treatment
show
significantli
higher
express
compar
noninfect
cell
fig
interestingli
highest
express
found
cell
treat
ritonavir
p
compar
treatment
p
hiv
infect
also
shown
import
factor
contribut
higher
level
cell
hiv
patient
fig
howev
contrast
demonstr
vitro
assay
express
protein
detect
noninfect
cell
blood
donor
addit
express
monocyteenrich
subpopul
hivinfect
volunt
significantli
higher
cell
healthi
control
arv
treatment
seem
key
factor
express
howev
lymphocyt
subpopul
combin
hiv
infect
arv
therapi
shown
import
particular
lymphocyt
hivinfect
patient
show
significantli
higher
express
compar
control
group
case
found
vitro
assay
pbmc
arv
therapi
led
higher
express
p
compar
express
healthi
control
group
p
comparison
vitro
vivo
result
indic
similar
dynam
hiv
infect
viru
seem
respons
higher
express
presenc
arv
drug
also
signific
howev
arv
therapi
suffici
induc
phosphoryl
indic
vitro
assay
therefor
infect
pbmc
treat
arv
drug
differ
express
profil
noninfect
treat
pbmc
pbmc
healthi
volunt
submit
hiv
infect
differ
arv
treatment
condit
express
phosphoryl
form
one
major
sensor
upr
pathway
analyz
phosphoryl
also
repres
activ
one
import
downstream
effect
activ
splice
mrna
condit
translat
import
transcript
factor
induc
express
er
stressrespons
gene
present
studi
vitro
assay
hiv
infect
abl
induc
express
pbmc
regardless
presenc
absenc
arv
drug
fig
howev
upregul
significantli
higher
cell
incub
arv
drug
curious
case
treatment
restrict
lamivudin
shown
lead
higher
express
p
treatment
ritonavir
p
observ
vitro
assay
express
level
monocyt
lymphocyt
hivinfect
patient
higher
compar
level
cell
obtain
healthi
individu
fig
despit
chang
protein
express
profil
infect
cell
rel
control
group
express
detect
express
protein
significantli
higher
lymphocyt
patient
arv
therapi
p
comparison
vitro
vivo
condit
show
hiv
infect
upregul
express
also
synergist
effect
arv
drug
result
present
corrobor
previou
report
show
proteas
inhibitor
trigger
upr
also
present
new
evid
drug
nucleosid
transcriptas
inhibitor
use
work
lead
activ
pathway
one
three
major
sensor
upr
pathway
activ
cleavag
occur
golgi
apparatu
cleav
transcript
factor
lead
increas
express
uprrel
gene
includ
gene
encod
chaperon
bip
current
studi
western
blot
assay
perform
antibodi
capabl
detect
cleav
noncleav
form
vitro
vivo
assay
larger
amount
cleav
cell
infect
hiv
arv
therapi
significantli
affect
express
profil
protein
particular
express
cleav
hivinfect
pbmc
significantli
higher
p
compar
express
noninfect
pbmc
fig
monocyt
hivinfect
patient
show
higher
statist
significantli
higher
express
cleav
form
compar
monocyt
healthi
individu
fig
similar
phenotyp
observ
lymphocyt
although
express
cleav
significantli
higher
cell
hivinfect
patient
moreov
patient
show
slightli
higher
express
protein
p
compar
patient
arv
therapi
without
proteas
inhibitor
p
proteas
inhibitor
p
cleavag
result
vitro
vivo
assay
suggest
hiv
respons
activ
upr
pathway
sensor
aim
contribut
better
understand
upr
activ
caus
hiv
studi
focus
hiv
target
cell
variabl
arv
treatment
set
vitro
vivo
condit
gener
increas
bip
express
observ
vitro
hivinfect
pbmc
well
cell
monocyt
hiv
patient
fig
bip
er
chaperon
involv
protein
fold
also
upr
activ
certain
viral
infect
alreadi
report
lead
increas
bip
express
includ
member
flavivirida
famili
dengu
viru
denv
west
nile
viru
wnv
hcv
addit
cmv
enteroviru
higher
bip
express
strong
indic
er
stress
need
better
fold
capac
via
upr
activ
present
studi
absenc
signific
differ
bip
express
cell
free
pharmacolog
treatment
arvtreat
cell
lack
signific
impact
arv
drug
noninfect
cell
strongli
suggest
hiv
sole
respons
stress
observ
er
case
infect
cell
patient
arv
therapi
despit
undetect
viral
load
perman
stress
probabl
relat
continu
presenc
proinflammatori
cytokin
present
pharmacolog
condit
found
bip
show
higher
express
activ
form
hivinfect
cell
regardless
pharmacolog
condit
fig
activ
lead
higher
express
protein
foldingrel
gene
bip
activ
alreadi
describ
cell
infect
ebv
hcv
denv
lymphocyt
choriomening
viru
lcmv
wnv
consid
role
transcript
activ
bip
express
reason
relat
greater
abund
cleav
state
infect
cell
consequ
increas
bip
express
enhanc
proteinfold
capabl
er
lumen
upr
sensor
show
differ
express
profil
observ
bip
two
molecul
pharmacolog
condit
seem
import
factor
modifi
protein
express
profil
differ
cell
group
fig
specif
tendenc
toward
increas
express
observ
noninfect
pbmc
treat
proteas
inhibitor
rtv
regardless
presenc
second
drug
compar
cell
submit
arv
drug
addit
nontreat
infect
pbmc
compar
nontreat
cell
noninfect
group
increas
level
observ
howev
comparison
differ
signific
among
hivinfect
pbmc
significantli
higher
express
found
cell
submit
arvmedi
pharmacolog
control
vivo
condit
lymphocyt
significantli
higher
express
monocyt
particularli
among
cell
obtain
patient
undergo
arv
treatment
scenario
interest
perk
phosphoryl
latter
factor
deactiv
simultan
phosphoryl
also
increas
translat
induc
express
sever
uprrel
gene
includ
bip
event
lead
attenu
protein
translat
decreas
load
new
protein
fold
er
lumen
accumul
phosphoryl
form
infect
cell
must
consid
strategi
avoid
excess
protein
fold
er
lumen
caselli
et
al
previous
suggest
promot
favor
environ
hiv
replic
presenc
may
also
lead
viru
reactiv
reservoir
gut
lymphoid
tissu
consid
role
disrupt
hiv
latenc
result
obtain
patient
undergo
arv
therapi
suggest
propiti
environ
hiv
accord
describ
role
previou
studi
unexpect
perspect
cell
pharmacolog
control
nevertheless
alreadi
known
arv
drug
capabl
induc
er
stress
upr
activ
rais
possibl
higher
upr
activ
signal
treat
cell
compar
cell
without
treatment
due
pharmacolog
upr
activ
differ
express
profil
monocyt
lymphocyt
could
relat
discrep
hiv
replic
cycl
two
cell
type
well
known
monocyt
macrophag
resist
hiv
infect
cytopath
effect
comparison
lymphocyt
refractori
behavior
favor
latenc
role
monocyt
macrophag
reservoir
even
patient
detect
viral
load
possibl
recov
reactiv
hiv
replic
cell
type
consid
hiv
play
role
phosphoryl
lack
signific
express
monocyt
may
relat
less
effici
hiv
replic
cell
contrast
activ
lymphocyt
permiss
cellular
target
hiv
infect
cell
die
apoptosi
howev
frequenc
infect
lymphocyt
clinic
condit
rel
low
permiss
lymphocyt
repres
less
whole
lymphocyt
popul
data
suggest
progress
loss
lymphocyt
occur
mechan
fact
alreadi
describ
approxim
cell
death
hiv
patient
occur
highli
inflammatori
mechan
call
pyroptosi
happen
less
permiss
cell
highli
inflammatori
environ
establish
even
patient
submit
arv
therapi
undetect
viral
load
begin
hiv
infect
massiv
deplet
memori
lymphocyt
gastrointestin
mucosa
deplet
facilit
transloc
microbi
product
gut
blood
creat
constant
sourc
immun
activ
inflamm
persist
arv
treatment
therefor
lymphocyt
hiv
patient
constant
metabol
stress
presenc
indic
condit
mention
current
studi
express
show
similar
profil
express
fig
phosphoryl
form
indic
activ
upr
sensor
respons
select
splice
mrna
gener
expect
activ
lead
higher
amount
express
protein
degradationrel
gene
decreas
proteinfold
workload
er
phosphoryl
alreadi
describ
avian
coronaviru
infecti
bronchiti
viru
ibv
ebv
cmv
hcv
wnv
infect
state
protein
degrad
creat
cell
advantag
viral
replic
evad
cellular
stress
respons
certain
virus
cmv
hcv
suppress
activ
avoid
induct
target
gene
ibvinfect
cell
activ
serv
surviv
factor
coronaviru
infect
protect
cell
apoptosi
higher
express
treat
patient
undetect
viral
load
lower
express
individu
observ
current
studi
agreement
activ
sensor
serv
cellular
defens
mechan
howev
studi
necessari
elucid
whether
hiv
also
employ
strategi
prevent
possibl
loss
replic
condit
entir
scenario
upr
activ
present
studi
reveal
higher
express
bip
pbmc
well
cell
patient
regardless
arv
treatment
wherea
activ
two
upr
sensor
perk
arv
treatment
depend
fig
infect
cell
submit
arv
therapi
bip
present
higher
express
level
infect
cell
arv
treatment
includ
pbmc
cultur
vitro
lymphocyt
volunt
patient
highest
level
upr
activ
present
trigger
activ
three
pathway
sensor
perk
repres
result
suggest
environ
activ
hiv
replic
upr
pathway
modul
viru
although
exact
mechan
complet
understood
result
present
indic
hiv
affect
upr
activ
three
major
sensor
perk
hivinfect
cell
upregul
uprrel
protein
way
seem
independ
arv
treatment
submit
howev
synergist
pharmacolog
effect
appear
occur
drug
show
influenc
protein
express
profil
noninfect
cell
vitro
vivo
condit
find
suggest
two
possibl
concurr
mechan
interfer
hiv
pharmacolog
effect
arv
drug
act
activ
upr
report
present
new
evid
hiv
modul
upr
pathway
enhanc
replic
secur
infect
success
also
rais
promis
possibl
use
pathway
drug
target
develop
new
antivir
therapi
studi
approv
intern
review
board
centro
de
hematologia
e
hemoterapia
de
santa
catarina
hemosc
brazil
hospit
region
dr
homero
de
miranda
gome
hrhmg
brazil
centro
de
testagem
e
aconselhamento
cta
brazil
ethic
committe
universidad
feder
de
santa
catarina
ufsc
brazil
oswaldo
cruz
fiocruz
rio
de
janeiro
brazil
studi
subject
provid
written
inform
consent
prior
enrol
studi
sampl
consist
individu
elig
volunt
includ
individu
year
old
recruit
hemosc
hrhmg
cta
individu
select
april
juli
volunt
arrang
four
distinct
group
hivneg
blood
donor
c
n
ii
hivposit
patient
tn
n
mean
viral
load
copiesml
iii
hivposit
patient
arv
therapi
without
proteas
inhibitor
tnpi
n
undetect
viral
load
iv
hivposit
patient
arv
therapi
includ
proteas
inhibitor
tpi
n
undetect
viral
load
infect
epsteinbarr
viru
ebv
cytomegaloviru
cmv
hepat
c
viru
hcv
herp
simplex
viru
human
herp
viru
acut
infect
consid
exclus
criteria
group
describ
clinic
data
hivposit
patient
access
medic
record
vivo
assay
wholeblood
sampl
enrol
volunt
collect
edta
tube
lymphocyt
monocyt
isol
peripher
blood
mononuclear
cell
pbmc
use
rosettesep
human
cell
enrich
cocktail
rosettesep
human
monocyt
enrich
cocktail
kit
stemcel
technolog
respect
cell
puriti
determin
use
fluorochromelabel
antibodi
bd
pharmingen
facscalibur
flow
cytomet
becton
dickinson
softwar
flowjo
tree
star
addit
file
figur
pbmc
healthi
donor
obtain
densiti
gradient
centrifug
hystopaqu
sigma
buffycoat
prepar
pbmc
resuspend
rpmi
lgc
bio
supplement
heatinactiv
fetal
bovin
serum
fb
hyclon
logan
ut
penicillin
uml
streptomycin
mm
glutamin
mm
hepe
follow
stimul
phytohemagglutinin
pha
sigma
day
mainten
cultur
medium
contain
uml
recombin
human
sigma
pbmc
infect
isol
bal
use
ngml
antigen
h
incub
cell
wash
remov
excess
viru
cultur
medium
ad
infect
pbmc
follow
treatment
arv
drug
last
throughout
infect
period
next
replic
evalu
cell
cultur
supernat
day
infect
use
commerci
elisa
kit
zeptometrix
co
cell
divid
group
untreat
cell
ii
cell
treat
nucleosid
revers
transcriptas
inhibitor
iii
cell
treat
proteas
inhibitor
ritonavirrtv
iv
cell
treat
rtv
addit
noninfect
cell
submit
differ
condit
describ
use
control
cellular
protein
lysat
prepar
lymphocyt
monocyt
enrich
subpopul
use
system
life
technolog
proteas
inhibitor
cocktail
sigmaaldrich
ad
result
lysat
store
vitro
assay
pbmc
suspend
lysi
buffer
compos
mm
ph
proteas
phosphatas
inhibitor
cocktail
sigmaaldrich
incub
min
follow
centrifug
g
min
supernat
collect
store
protein
quantif
perform
via
bicinchonin
acid
bca
method
use
micro
bca
protein
assay
kit
pierc
actual
measur
perform
spectrophotometri
nm
use
infinit
micropl
reader
tecan
total
cellular
protein
lysat
sampl
separ
sdspage
electroblot
onto
nitrocellulos
membran
ge
healthcar
soak
blot
buffer
mm
tri
mm
glycin
methanol
ph
subsequ
membran
incub
h
rabbit
antiactin
abcam
mous
antibip
abcam
rabbit
abcam
rabbit
abcam
mous
abcam
blot
incub
hrpconjug
antimous
antirabbit
total
immunoglobulin
respect
abcam
h
detect
perform
use
ecl
reagent
pierc
exposur
radiograph
film
ge
healthcar
develop
perform
use
autom
processor
konica
minolta
quantit
analysi
data
obtain
western
blot
experi
perform
band
densitometri
use
softwar
imagej
http
rsbwebnihgovij
data
present
mean
standard
deviat
sd
result
plot
submit
statist
analysi
anova
parametr
test
observ
consid
statist
signific
p
statist
analys
perform
use
softwar
graphpad
graph
drawn
graphpad
prism
version
